Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roelf Valkema

Showing results (11-20 of 100) with videos related to

Pageof 10
Sort By:
European Heart Journal. Cardiovascular Imaging|January 22, 2016
Dobutamine stress myocardial perfusion imaging: 8-year outcomes in patients with diabetes mellitusHendrik J Boiten, Ron T van Domburg, Roelf Valkema, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 17, 2002
Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginineEdgar J Rolleman, Roelf Valkema, Marion de Jong, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 18, 2005
Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogsMarion de Jong, Wout A P Breeman, Roelf Valkema, et al.
Accounts of Chemical Research|May 19, 2009
Tumor imaging and therapy using radiolabeled somatostatin analoguesMarion de Jong, Wout A P Breeman, Dik J Kwekkeboom, et al.
The American Journal of Cardiology|September 9, 2015
Eight-Year Prognostic Value of QRS Duration in Patients With Known or Suspected Coronary Artery Disease Referred for Myocardial Perfusion ImagingRoy Huurman, Hendrik J Boiten, Roelf Valkema, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|July 7, 2016
Prediction of 14-year cardiovascular outcomes by dobutamine stress <sup>99m</sup>Tc-tetrofosmin myocardial perfusion SPECT in elderly patients unable to perform exercise testingStefan Roest, Hendrik J Boiten, Ron T van Domburg, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 7, 2005
Oral versus intravenous administration of lysine: equal effectiveness in reduction of renal uptake of [111In-DTPA]octreotideSuzanne M Verwijnen, Eric P Krenning, Roelf Valkema, et al.
Annals of the New York Academy of Sciences|May 22, 2004
Peptide receptor radionuclide therapyEric P Krenning, Dik J Kwekkeboom, Roelf Valkema, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 17, 2009
Kidney protection during peptide receptor radionuclide therapy with somatostatin analoguesEdgar J Rolleman, Marleen Melis, Roelf Valkema, et al.
The American Journal of Cardiology|February 19, 2004
Prediction of all-cause mortality in women with known or suspected coronary artery disease by stress technetium-99m tetrofosmin myocardial perfusion imagingAbdou Elhendy, Arend F L Schinkel, Ron T van Domburg, et al.
Pageof 10

Showing results (11-20 of 100) with videos related to

Sort By:
Pageof 10
European Heart Journal. Cardiovascular Imaging|January 22, 2016
Dobutamine stress myocardial perfusion imaging: 8-year outcomes in patients with diabetes mellitusHendrik J Boiten, Ron T van Domburg, Roelf Valkema, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 17, 2002
Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginineEdgar J Rolleman, Roelf Valkema, Marion de Jong, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 18, 2005
Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogsMarion de Jong, Wout A P Breeman, Roelf Valkema, et al.
Accounts of Chemical Research|May 19, 2009
Tumor imaging and therapy using radiolabeled somatostatin analoguesMarion de Jong, Wout A P Breeman, Dik J Kwekkeboom, et al.
The American Journal of Cardiology|September 9, 2015
Eight-Year Prognostic Value of QRS Duration in Patients With Known or Suspected Coronary Artery Disease Referred for Myocardial Perfusion ImagingRoy Huurman, Hendrik J Boiten, Roelf Valkema, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|July 7, 2016
Prediction of 14-year cardiovascular outcomes by dobutamine stress <sup>99m</sup>Tc-tetrofosmin myocardial perfusion SPECT in elderly patients unable to perform exercise testingStefan Roest, Hendrik J Boiten, Ron T van Domburg, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 7, 2005
Oral versus intravenous administration of lysine: equal effectiveness in reduction of renal uptake of [111In-DTPA]octreotideSuzanne M Verwijnen, Eric P Krenning, Roelf Valkema, et al.
Annals of the New York Academy of Sciences|May 22, 2004
Peptide receptor radionuclide therapyEric P Krenning, Dik J Kwekkeboom, Roelf Valkema, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 17, 2009
Kidney protection during peptide receptor radionuclide therapy with somatostatin analoguesEdgar J Rolleman, Marleen Melis, Roelf Valkema, et al.
The American Journal of Cardiology|February 19, 2004
Prediction of all-cause mortality in women with known or suspected coronary artery disease by stress technetium-99m tetrofosmin myocardial perfusion imagingAbdou Elhendy, Arend F L Schinkel, Ron T van Domburg, et al.
Pageof 10